Introduction
============

The incidence and mortality of certain cancers in China have been increasing at an alarming speed. Lung cancer is still the most common incident cancer and the leading cause of cancer death.[@b1-cmar-11-2225] Numerous studies have demonstrated that the incidence of malnutrition among cancer patients is as high as 31%--97%.[@b2-cmar-11-2225]--[@b6-cmar-11-2225] Studies on malnutrition in cancer patients are common in gastrointestinal tumors and relatively few in lung cancer patients. Xará et al found that the incidence of malnutrition among patients with non-small-cell lung cancer (NSCLC) was 35.7%.[@b7-cmar-11-2225] The consequences of malnutrition may be reduced immune function, increased infection rates, decreased response and tolerance to treatment, higher health care costs, a lower quality of life, and reduced survival time.[@b8-cmar-11-2225]--[@b11-cmar-11-2225] Furthermore, the relative risk of death from malnutrition has been found to be 1.8 times higher than for cancer patients without malnutrition.[@b12-cmar-11-2225] Hence, it is important to consider nutritional status in cancer management, since it decides the patient's tolerance for curative treatment.[@b13-cmar-11-2225]

Traditional nutritional assessment is often difficult because non-nutritional factors can obscure the influences of actual nutrient deprivation. Therefore, the Subjective Global Assessment (SGA), an easy-to-use and a noninvasive clinical tool, has been developed. The SGA is a clinical technique that combines data from subjective and objective aspects of medical history (weight change, subcutaneous fat loss, muscle wasting, ankle or sacral edema, and ascites).[@b14-cmar-11-2225] The scored Patient-Generated Subjective Global Assessment (PG-SGA) is a modified version of the SGA, which is specifically designed for assessing the nutritional status in cancer patients.[@b15-cmar-11-2225]--[@b17-cmar-11-2225] It contains additional problems regarding the existence of nutritional symptoms and short-term weight loss. The PG-SGA is a validated instrument to assess and monitor malnutrition, which is made up of both patient-reported and professional-reported items. The scored PG-SGA is formed from total PG-SGA score and global assessment. The total PG-SGA score is the sum of scores of the following seven items -- weight loss, disease, food intake, nutrition impact symptoms, activities and function, metabolic demand, and physical examination. The scored PG-SGA has been accepted by the Oncology Nutrition Dietetic Practice Group of the American Dietetic Association as the standard for nutrition assessment for patients with cancer.

The sum of scores obtained in each domain of the PG-SGA is used to determine the total PG-SGA score. After consultation, the dietitians rank the nutritional status of the patients as follows: 0--1, nutritional support not required and treatment in the future based on routine re-evaluation; 2--3, dietary guidance for patients and their families by a nutritionist, with assistance from nurses or other health care professionals based on symptom investigation and laboratory examination; 4--8, nutritional support provided by a dietitian with assistance from nurses or physicians according to the symptom questionnaire; ≥9, urgent need for improved symptom management and/or nutritional support.[@b18-cmar-11-2225] Nutritional status is assessed by the PG-SGA category, which classifies patients into one of three categories: 0--1, well-nourished (PG-SGA A); 2--8, suspected malnutrition or moderate malnutrition (PG-SGA B); ≥9, severely malnourished (PG-SGA C).[@b19-cmar-11-2225]--[@b21-cmar-11-2225] The higher the PG-SGA score is, the greater is the risk for malnutrition.[@b18-cmar-11-2225]

Malnutrition is a common phenomenon among patients with cancer, but it is often ignored in the treatment and follow-up care.[@b22-cmar-11-2225] The comprehensive approach to nutrition support may lead to improvements in nutritional status, quality of life, patient satisfaction, and treatment outcomes. The aims of the present study were to evaluate the nutritional status and possible relevant factors and provide the basic information for further studies regarding nutritional assessment of patients with lung cancer.

Patients and methods
====================

This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee at the Harbin Medical University. All patients gave written informed consent before their participation in the study.

Patient and public involvement
------------------------------

The participants of this study were lung cancer patients who were newly confirmed by pathological examination. Advanced lung cancer is defined as TNM stage IIIB and IV. We use the eighth edition lung cancer TNM staging system for staging. Patients who had only best supportive care, as well as those with cognitive impairment or other acute psychological problems, were excluded. Assessment of the nutritional status in patients was done within 24 hours after admission to the hospital. The subjects had records of weight history for the previous 6 months. Data on a wide range of variables including demographic factors, and nutritional status and nutrition-related symptoms were collected.

Follow-up
---------

All patients were routinely followed every 3 months in the first 2 years. All patients were followed up using outpatient clinic check-ups. The latest follow-up was in June 2017, and the median follow-up duration was 12.6 months (range 1--60). Overall survival (OS) was calculated from the date of diagnosis until death or the last available follow-up. OS is considered to be the best efficacy endpoint in clinical trials for cancer, and it is the preferred endpoint when the patient's survival is adequately assessed. This study investigated the clinical significance of PG-SGA scores at admission by following OS.

Statistical analysis
--------------------

We administered a PG-SGA standard questionnaire for patients with advanced lung cancer who were admitted to the Lung Medical Oncology Unit at Harbin Cancer Hospital. Statistical analysis was performed using SPSS version 17 (SPSS Institute, Inc.). The PG-SGA scores emerged as descriptive statistics (mean, SDs, and percentage). The degree of relationship among these factors and PG-SGA scores was statistically evaluated using the independent *t*-test (sex, TNM stage, smoking condition, albumin, and pre-albumin), Wilcoxon signed-rank test (age, pathology, and anemia), and Kruskal--Wallis test (body mass index \[BMI\]). Kaplan--Meier survival analysis and the log-rank test were used to calculate the OS. Univariate and multivariate analyses of the OS were performed using Cox analysis. Two-tailed *P*\<0.05 was considered statistically significant.

Results
=======

The study group consisted of 495 patients aged 28--79 years with advanced lung cancer. All patients with advanced lung cancer were confirmed by pathological diagnosis. Also, 70.7% (350) of the patients were male and 29.3% (145) were female. Sixty-two percent (307) of the patients had a pathological diagnosis of NSCLC and 38.0% (188) were pathologically diagnosed as small-cell lung cancer (SCLC). Patients with TNM stage IV constituted 66.7% (330) and 33.3 (165) patients were stage IIIB. Also, 88.9% (440) of the patients had a history of smoking and only 11.1% (55) had no history of smoking. There were 140 patients with BMI \<18.5 kg/m^2^ and 115 with BMI ≥25.0 kg/m^2^. There were 193 patients with anemia, 152 with pre-serum albumin \<20 mg/ dL, and 132 with serum albumin \<35 g/L.

The PG-SGA score was calculated and the scores ranged between 0 and 35. Based on the total scores, nutritional status of the patients was divided into four parts. In this study, only 11.1% of the patients did not need nutritional intervention (scores 0--1), 10.5% of them needed health education (scores 2--3), 53.3% of them needed nutritional support (scores 4--8), and 25.1% needed nutrition-related symptom management and (or) nutritional support urgently (score ≥9). [Table 1](#t1-cmar-11-2225){ref-type="table"} summarizes the nutritional status of the study group. Participants received corresponding nutrition intervention based on the PG-SGA score after completing the PG-SGA.

Weight loss was the most frequently used nutritional assessment method, which was measured solely or in combination with PG-SGA.[@b23-cmar-11-2225]--[@b25-cmar-11-2225] In our study, severe weight loss was observed in 7% of the patients (weight loss of \>10% in 1 month or \>20% in 6 months), and weight loss continued to occur in 80.4% of the patients. Also, 58.8% of the patients had varying degrees of difficulty in eating food. Nearly half (50.1%) of the patients had reduced food intake, 6.5% had pap food, and 2.2% had only liquid food. Only 17.2% of the patients had no nutrition impact symptoms. Among all patients, 57.2% had choking and 59% had appetite loss, vomiting, and diarrhea. Overall, 62.4% of the patients had impaired function and ability. Among them, 7.3% could lie or sit for more than half a day. Of the subjects, 61.8% reported fat loss, with the condition being severe in 11.7%. Additionally, 16.4% of the patients experienced severe stress and 28.3% of the patients had pleural effusion or ascites. The characteristics of the patient cohort are summarized in detail in [Table 2](#t2-cmar-11-2225){ref-type="table"}.

[Table 3](#t3-cmar-11-2225){ref-type="table"} summarizes the relationship between PG-SGA scores and possible related factors. An elevated PG-SGA score was associated with age ≥60 years (*P*=0.026), female patients (*P*\<0.001), SCLC, smoking, presence of anemia (*P*\<0.001), higher TNM stage (*P*\<0.001), and lower BMI, pre-albumin, and albumin.

The treatment regimen for 495 patients with advanced lung cancer is shown in [Table 4](#t4-cmar-11-2225){ref-type="table"}.

The median follow-up duration was 12.6 months (range 1--60). Of all participants, 413 patients had died. Patients with the PG-SGA scores of 0--1 had significantly longer mean survival compared to patients with PG-SGA scores greater than 1 (*P*\<0.001; [Figure 1](#f1-cmar-11-2225){ref-type="fig"}). In age- and sex-matched analysis, the PG-SGA scores were still associated with OS (*P*\<0.001, respectively; [Figure 2](#f2-cmar-11-2225){ref-type="fig"}). An elevated PG-SGA score was associated with reduced survival of both young and old lung cancer patients. Univariate and multivariate analyses for OS outcomes are shown in [Table 5](#t5-cmar-11-2225){ref-type="table"}.

Discussion
==========

Malnutrition frequently coexists in cancer patients. The results of our study ([Table 1](#t1-cmar-11-2225){ref-type="table"}) showed that 25.1% of the patients need nutrition-related symptom management and/ or nutritional support urgently. Moreover, only 11.1% of the patients with advanced lung cancer do not need nutritional intervention. Our findings indicate that malnutrition is prevalent in advanced lung cancer patients, and these patients require timely nutrition education and guidance, treatment for symptoms, such as drug interventions, and proper nutritional support.

Data summarized in [Table 2](#t2-cmar-11-2225){ref-type="table"} reveal that advanced lung cancer patients experience various degrees of weight loss. Severe weight loss was found in 7% of the patients (weight loss of \>10% in 1 month or \>20% in 6 months), and weight loss continued to occur in nearly four-fifths (80.4%) of the patients. Weight loss indicates poor treatment response and contributes to mortality in lung cancer.[@b26-cmar-11-2225]--[@b28-cmar-11-2225] In this study, 58.8% of the patients had difficulty with eating food, including 6.5% who could consume pap food and 2.2% who could consume only liquid food. Many patients with advanced lung cancer were consuming diets that would likely be insufficient to maintain weight even in healthy individuals. The results showed that 61.8% of the patients had a reduction in fat, with the most severe case showing a reduction of 11.7%. Patients with lung cancer have higher consumption of protein and fat, which could lead to weight loss. Significant weight loss may result in increased rate of complications, such as impaired wound healing, reduced immune function, and decreased tolerance to surgery, radiotherapy, and chemotherapy, as well as reduced quality of life.[@b29-cmar-11-2225]--[@b31-cmar-11-2225] Our data show that 82.8% of the advanced lung cancer patients had nutrition impact symptoms, including nausea or fullness (9.1%), choking (57.2%), appetite loss, vomiting, and diarrhea (59.0%). These symptoms might relate with metabolic problems that are induced by advanced lung cancer. Additionally, 16.4% of the patients experienced severe stress; these patients should be given appropriate psychological intervention treatment. Also, 28.3% of the patients had pleural effusion or ascites. The cause of pleural effusion or ascites might be the following: lung cancer metastasizes to the pleura, resulting in increased pleural secretion, which leads to effusion, and patients with advanced lung cancer may suffer from malnutrition and decrease in serum albumin, which may lead to effusion.

The present study demonstrates that elderly patients (≥60) and female patients would be more likely to have malnutrition. The research shows that patients who had a history of smoking showed higher malnutrition than the patients who had no history of smoking. Malnutrition may be associated with smoking as it is the inducing factor of many diseases. Therefore, more attention should be paid to the patients who have a history of smoking, and smoking cessation support should be provided for these patients. Furthermore, we found that the PG-SGA score was associated with OS. Patients with PG-SGA scores of 0--1 had significantly longer mean survival. These findings were supported by other studies, which also found an association between nutritional status and clinical outcome. Alifano et al reported that nutritional status and tumor immune micro-environment determine the outcome of resected NSCLC.[@b32-cmar-11-2225] Tan et al also found that nutritional status, which was assessed by PG-SGA, might be a determinant of prognosis in patients with advanced cancer.[@b33-cmar-11-2225] Given these results, we speculated that the PG-SGA score might exert more potent prognostic value.

A potential limitation of the current study is that it was a single-center analysis, and we lacked the data of progression-free survival, though OS is considered the gold standard endpoint for cancer prognosis study. Therefore, our findings might need to be confirmed with additional outcome measures. Further prospective studies are warranted to assess whether the PG-SGA can predict the risk of poor clinical outcomes such as dose--intensity of chemotherapy, quality of life, and survival in lung cancer patients. Patients with a high risk of malnutrition should be given more attention, and improvement of the nutritional status of patients with advanced lung cancer has beneficial effects on their quality of life.

Conclusion
==========

The present study aimed to assess the nutritional status of patients with advanced lung cancer, particularly those at a higher risk of malnutrition, such as elderly patients, female patients, SCLC patients, patients of TNM stage IV, and smokers, and poor nutritional status was associated with worse clinical outcomes.

Patients with a high risk of malnutrition should be given more attention; their nutritional status should be evaluated and they should be given nutrition education and necessary nutritional support in time. Improvement of the nutritional status of patients with advanced lung cancer may have beneficial effects on their quality of life.

The present study has several limitations. First, treatment of patients in this study is different, which may lead to differences in OS. Second, the heterogeneity of patients with NSCLC and SCLC has a certain impact on the OS of patients. These should be taken care of in the future.
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![Kaplan--Meier survival curves by PG-SGA scores in patients with advanced lung cancer.\
**Notes:** Log-rank between-group comparison *P*\<0.001. Cox analysis showed that the Cox risk ratio was 2.128 (95% CI: 1.855--2.440).\
**Abbreviation:** PG-SGA, Patient-Generated Subjective Global Assessment.](cmar-11-2225Fig1){#f1-cmar-11-2225}

![Overall survival based on PG-SGA scores in patients aged ≥60 years (**A**), \<60 years (**B**), male patients (**C**), and female patients (**D**), respectively.\
**Abbreviation:** PG-SGA, Patient-Generated Subjective Global Assessment.](cmar-11-2225Fig2){#f2-cmar-11-2225}

###### 

Patient-Generated Subjective Global Assessment classification (N=495)

  Classification (score)                                    Cases (n)   \%
  --------------------------------------------------------- ----------- ------
                                                                        
  Without intervention (0--1)                               55          11.1
  Need health education (2--3)                              52          10.5
  Need nutritional support (4--8)                           264         53.3
  Need symptom management and/or nutritional support (≥9)   124         25.1

###### 

Patient-Generated Subjective Global Assessment content (N=495)

  Characteristics of patient                                           Cases (n)   \%
  -------------------------------------------------------------------- ----------- ------
                                                                                   
  **Weight loss ratio (%**)[@b18-cmar-11-2225]                                     
  0--1.9                                                               186         37.6
  2--2.9 in 1 month or 2--5.9 in 6 months                              45          9.1
  3--4.9 in 1 month or 6--9.9 in 6 months                              136         27.5
  5--9.9 in 1 month or 10--19.9 in 6 months                            93          18.8
  ≥10 in 1 month or ≥20 in 6 months                                    35          7.0
  **Body weight loss in the recent 2 weeks**                                       
  Yes                                                                  398         80.4
  No                                                                   97          19.6
  **Food intake**                                                                  
  Normal                                                               204         41.2
  Reduced food intake                                                  248         50.1
  Pap                                                                  32          6.5
  Liquid food                                                          11          2.2
  **Nutrition impact symptoms**                                                    
  No                                                                   85          17.2
  Nausea and fullness                                                  45          9.1
  Choking                                                              283         57.2
  Appetite loss/vomiting/diarrhea                                      292         59.0
  **Functional capacity**                                                          
  Normal                                                               186         37.6
  Minor activities                                                     241         48.7
  Lying or sitting for less than half a day                            32          6.4
  Lying or sitting for more than half a day                            36          7.3
  **Loss of fat (tricipital skinfold thickness**)[@b18-cmar-11-2225]               
  No                                                                   189         38.2
  Mild                                                                 142         28.7
  Moderate                                                             106         21.4
  Severe                                                               58          11.7
  **Stress**                                                                       
  No                                                                   256         51.7
  Moderate                                                             158         31.9
  Severe                                                               81          16.4
  **Body fluids (pleural effusion and ascites**)[@b18-cmar-11-2225]                
  No                                                                   355         71.7
  Mild                                                                 82          16.6
  Moderate                                                             42          8.5
  Severe                                                               16          3.2

###### 

Analysis of PG-SGA score with factors affecting nutritional status

  Cases (n)             PG-SGA score   Statistical value   *P*-value    
  --------------------- -------------- ------------------- ------------ ---------
                                                                        
  Age (years)                                                           
   ≥60                  300            8±2.20                           
   \<60                 195            6±1.60              u=−2.226     0.026
  Sex                                                                   
   Male                 350            6±0.96                           
   Female               145            7±1.12              t=−9.254     \<0.001
  Type of lung cancer                                                   
   NSCLC                307            5±0.80                           
   SCLC                 188            7±0.64              u=−9.605     \<0.001
  TNM stage                                                             
   III B                165            5±1.09                           
   IV                   330            8±1.02              t=18.893     \<0.001
  Smoking condition                                                     
   Yes                  440            7±0.91                           
   No                   55             4±1.17              t=15.598     \<0.001
  Anemia                                                                
   Yes                  193            7±0.73                           
   No                   302            6±0.47              u=--12.006   \<0.001
  BMI (kg/m^2^)                                                         
   \<18.5               140            7±0.67                           
   ≥18.5 and \<25.0     240            6±0.42                           
   ≥25.0                115            4±0.68                           \<0.001
  Pre-albumin (mg/dL)                                                   
   \<20 mg/dL           152            8±0.49                           
   ≥20 mg/dL            343            6±0.54              *t*=55.708   \<0.001
  Albumin                                                               
   \<35 g/L             132            8±0.48                           
   ≥35 g/L              363            6±0.48              *t*=40.808   \<0.001

**Abbreviations:** BMI, body mass index; NSCLC, non-small-cell lung cancer; PG-SGA, Patient-Generated Subjective Global Assessment; SCLC, small-cell lung cancer.

###### 

Treatment regimen for advanced lung cancer

  Type of lung cancer                                                                                                                                                         Treatment regimen
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                              
  NSCLC                                                                                                                                                                       Targeted therapy
  Immunotherapy                                                                                                                                                               
  Immunotherapy and chemotherapy                                                                                                                                              
  Chemotherapy (pemetrexed + cisplatin/gemcitabine + cisplatin                                                                                                                
  /Paclitaxel + cisplatin/vinorelbine + cisplatin/docetaxel + cisplatin/pemetrexed + carboplatin/gemcitabine + carboplatin/paclitaxel + carboplatin/ gemcitabine/docetaxel)   
  Radiotherapy (three-dimensional conformal radiation therapy)                                                                                                                
  Chemotherapy and radiotherapy                                                                                                                                               
  SCLC                                                                                                                                                                        Chemotherapy (etoposide + cisplatin/etoposide + carboplatin/irinotecan + cisplatin/paclitaxel/ docetaxel/gemcitabine)
  Chemotherapy and radiotherapy (three-dimensional conformal radiation therapy)                                                                                               

**Abbreviations:** NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.

###### 

Univariate and multivariate analyses for OS outcomes

  Characteristics of patient             OS                     
  -------------------------------------- ------- -------------- ---------
                                                                
  **Univariate analysis**                                       
  Age (years)                                                   
   ≥60 vs \<60                           1.297   1.065--1.581   0.010
  Sex                                                           
   Male vs female                        0.457   0.367--0.569   \<0.001
  PG-SGA                                                        
   0--1 vs 2--3 vs 4--8 vs ≥9            2.128   1.855--2.440   \<0.001
  Type of lung cancer                                           
   NSCLC vs SCLC                         3.501   2.824--4.339   \<0.001
  TNM stage                                                     
   III B vs IV                           1.144   0.932--1.405   0.197
  Smoking condition                                             
   Yes vs no                             0.943   0.694--1.281   0.707
  Anemia                                                        
   Yes vs no                             1.125   0.922--1.373   0.245
  BMI (kg/m^2^)                                                 
   \<18.5 vs ≥18.5 and \<25.0 vs ≥25.0   1.098   0.960--1.256   0.173
  Pre-albumin (mg/dL)                                           
   \<20 vs ≥20                           1.038   0.843--1.277   0.726
  Albumin (g/L)                                                 
   \<35 vs ≥35                           0.562   0.451--0.700   \<0.001
  **Multivariate analysis**                                     
  Age (years)                                                   
   ≥60 vs \<60                           0.758   0.556--1.003   0.079
  Sex                                                           
   Male vs female                        0.338   0.259--0.441   \<0.001
  PG-SGA                                                        
   0--1 vs 2--3 vs 4--8 vs ≥9            1.857   1.583--2.180   \<0.001
  Type of lung cancer                                           
   NSCLC vs SCLC                         2.805   2.241--3.510   \<0.001
  Albumin (g/L)                                                 
   \<35 vs ≥35                           0.687   0.548--0.861   0.001

**Abbreviations:** BMI, body mass index; NSCLC, non-small-cell lung cancer; OS, overall survival; PG-SGA, Patient-Generated Subjective Global Assessment; SCLC, small-cell lung cancer.
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